Jack Meehan

Stock Analyst at Barclays

(3.06)
# 1,366
Out of 5,090 analysts
137
Total ratings
69.51%
Success rate
21.33%
Average return

Stocks Rated by Jack Meehan

Labcorp Holdings
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $275$290
Current: $258.39
Upside: +12.23%
Agilent Technologies
Feb 28, 2024
Maintains: Underweight
Price Target: $120$125
Current: $145.49
Upside: -14.08%
Waters
Aug 3, 2023
Maintains: Equal-Weight
Price Target: $275$288
Current: $394.81
Upside: -27.05%
Avantor
Mar 3, 2021
Initiates: Overweight
Price Target: $33
Current: $10.93
Upside: +201.92%
Illumina
Mar 3, 2021
Initiates: Underweight
Price Target: $325
Current: $128.96
Upside: +152.02%
InMode
Aug 17, 2020
Maintains: Overweight
Price Target: $18$19
Current: $14.42
Upside: +31.76%
Quest Diagnostics
Apr 23, 2020
Maintains: Equal-Weight
Price Target: $93$99
Current: $182.51
Upside: -45.76%
ICON Public Limited Company
Apr 23, 2020
Maintains: Overweight
Price Target: $170$180
Current: $185.80
Upside: -3.12%
Myriad Genetics
Mar 26, 2020
Maintains: Underweight
Price Target: $14$10
Current: $7.09
Upside: +41.04%
IQVIA Holdings
Mar 26, 2020
Maintains: Overweight
Price Target: $192$166
Current: $225.85
Upside: -26.50%
Maintains: Equal-Weight
Price Target: $51$43
Current: $74.97
Upside: -42.64%
Maintains: Equal-Weight
Price Target: $170$154
Current: $184.31
Upside: -16.45%
Maintains: Overweight
Price Target: $435$430
Current: $317.69
Upside: +35.35%
Maintains: Overweight
Price Target: $435$430
Current: $317.05
Upside: +35.63%
Downgrades: Equal-Weight
Price Target: n/a
Current: $27.76
Upside: -
Upgrades: Overweight
Price Target: $52$48
Current: $48.03
Upside: -0.06%
Upgrades: Equal-Weight
Price Target: $720$680
Current: $1,414.86
Upside: -51.94%
Maintains: Underweight
Price Target: $28$30
Current: $78.37
Upside: -61.72%
Maintains: Overweight
Price Target: $295$300
Current: $572.77
Upside: -47.62%
Initiates: Equal-Weight
Price Target: $40
Current: $1.36
Upside: +2,841.18%